Writing Group Disclosures

Writing Group MemberEmploymentResearch GrantOther Research SupportSpeakers’ Bureau/HonorariaExpert WitnessOwnership InterestConsultant/Advisory BoardOther
Joyce A. WahrUniversity of MichiganAHRQ*NoneNoneNoneNoneNoneNone
Nancy A. NussmeierSUNY Upstate Medical UniversityNoneNoneNoneNoneNoneNoneNone
J.H. Abernathy IIIMedical University of South CarolinaNoneNonePharMEDium*NoneNoneNoneNone
Michael H. CuligWest Penn Allegheny Health SystemNoneNoneNoneNoneNoneNoneNone
Pirooz EghtesadyWashington University, St. LouisNoneNoneNoneNoneNoneNoneNone
Michael R. EnglandPhysician’s Organization at Tufts Medical CenterNoneNoneHospiraNoneSafePath Medical; Echo TherapeuticsNoneNone
David C. FitzgeraldInova Heart and Vascular InstituteNoneNoneNoneNoneNoneNoneNone
John S. IkonomidisMedical University of South CarolinaNoneNoneNoneNoneNoneNoneNone
Robert C. GroomMaine Medical CenterNoneNoneVarious honoraria from nonprofit anesthesia, perfusion, and surgery societies*Expert witness for defense (industry), CPB-related accidents; 2 ongoing cases witness for defense (hospital)*NoneFDA consultant on device issue*Editor-in-Chief, Journal of ExtraCorporeal Technology*; treasurer for AmSECT*
Elizabeth H. LazzaraUniversity of Central FloridaTBDTBDTBDTBDTBDTBDTBD
Elizabeth A. MartinezMassachusetts General HospitalAHRQNoneNoneNoneNoneNoneNone
Richard L. PragerUniversity of MichiganNoneNoneNoneNoneNoneNoneNone
Eduardo SalasUniversity of Central FloridaNoneNoneNoneNoneNoneNoneNone
Juan A. SanchezSt. Agnes Hospital, Johns Hopkins School of MedicineNoneNoneNoneNoneNoneNoneNone
Bruce E. SearlesSUNY Upstate Medical UniversityTransonic Systems; Circulatory TechnologiesNoneNoneExpert witness for defense in 2010 and 2011 for standards of care for perfusion practice†NoneNoneNone
Patricia C. SeifertInova Heart and Vascular InstituteNoneNoneNoneNoneNoneNoneNone
Frank W. SellkeLifespan/Brown Medical SchoolNoneNoneNoneExpert witness for defendant in aortic dissection case*NoneCLS Behring*; Novo Nordisk*; Regado*; The Medicines Co*None
Scott A. ShappellClemson UniversityNoneNoneNoneNoneNoneNoneNone
Bruce D. SpiessVirginia Commonwealth University Medical CenterNoneNoneNoneNoneNoneNoneNone
Thoralf M. Sundt IIIMassachusetts General HospitalNoneNoneNoneNoneNoneNoneNone
Vinod H. ThouraniEmory UniversityAHA*; Edwards Lifesciences*; Maquet Medical*; NIH*NoneEdwards Lifesciences*; Maquet Medical*; Sorin Medical*; St. Jude Medical*NoneOwner and founder of Apica Cardiovascular* (start-up company)Maquet Medical*; St. Jude Medical*None
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.